SCHEMBL23818597

SCHEMBL23818597

CCOC(=O)[C@H](C)NP(=O)(N[C@@H](C)C(=O)OCC)Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 2/20 0.52
▸ CA2 P00918 2/20 0.52
▸ BCHE P06276 1/20 0.52
▸ ACHE P22303 1/20 0.52
▸ MAPT P10636 6/20 0.50
▸ CRHBP P24387 1/20 0.50
▸ CRHR2 Q13324 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ ALDH1A1 P00352 4/20 0.48
▸ CYP3A4 P08684 2/20 0.48
▸ MAPK1 P28482 2/20 0.48
▸ HSD17B10 Q99714 2/20 0.48
▸ TSHR P16473 1/20 0.48
▸ CES2 O00748 1/20 0.48
▸ CES1 P23141 1/20 0.48
▸ KDM4E B2RXH2 2/20 0.46
▸ GAA P10253 1/20 0.46
▸ LMNA P02545 2/20 0.45
▸ TP53 P04637 1/20 0.45
▸ THRB P10828 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23818598 0.89 MGLL (0.47) CA1CA2BCHEACHEMAPT
SCHEMBL23819198 0.88 ALDH1A1 (0.51) CA1CA2BCHEACHEMAPT
SCHEMBL12621313 0.88 CA1 (0.50) CA1CA2BCHEACHEMAPT
SCHEMBL16566194 0.87 CA1 (0.45) CA1CA2BCHEACHEMAPT
SCHEMBL28854863 0.87 BTN3A1 (0.50) CA1CA2BCHEACHEMAPT
SCHEMBL10149592 0.87 BTN3A1 (0.50) CA1CA2BCHEACHEMAPT
SCHEMBL30089933 0.87 BTN3A1 (0.50) CA1CA2BCHEACHEMAPT
SCHEMBL16566193 0.86 CA1 (0.49) CA1CA2BCHEACHEMAPT
SCHEMBL17198688 0.86 CA1 (0.48) CA1CA2BCHEACHEMAPT
SCHEMBL26277253 0.85 CA1 (0.43) CA1CA2BCHEACHEMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11767337-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2023-09-26 — — US disclosed
US-11767337-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2023-09-26 — — US disclosed
US-20230295201-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2023-09-21 — — US disclosed
US-20230295201-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2023-09-21 — — US disclosed
US-20210284670-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2021-09-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295201-A1 ANTIVIRAL COMPOUNDS MAVS, HAVCR2, ZC3HAV1 CA1 4866/4885CA2 4718/4885BCHE 1791/4885
US-20210284670-A1 ANTIVIRAL COMPOUNDS MAVS, HAVCR2, ZC3HAV1 CA1 4866/4885CA2 4718/4885BCHE 1791/4885
US-11767337-B2 Antiviral compounds MAVS, HAVCR2, ZC3HAV1 CA1 4866/4885CA2 4718/4885BCHE 1791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback